Page last updated: 2024-10-17

coumarin and Tuberculosis, Multidrug-Resistant

coumarin has been researched along with Tuberculosis, Multidrug-Resistant in 2 studies

2H-chromen-2-one: coumarin derivative

Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Alghamdi, S1
Rehman, SU2
Shesha, NT1
Faidah, H1
Khurram, M1
Reddy, DS1
Kongot, M1
Kumar, A1

Reviews

2 reviews available for coumarin and Tuberculosis, Multidrug-Resistant

ArticleYear
Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
    Molecules (Basel, Switzerland), 2020, Dec-02, Volume: 25, Issue:23

    Topics: Animals; Antitubercular Agents; Coumarins; Drug Design; Humans; Isoniazid; Mycobacterium tuberculosi

2020
Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Tuberculosis (Edinburgh, Scotland), 2021, Volume: 127

    Topics: Animals; Antitubercular Agents; Coumarins; Drug Design; Drug Resistance, Bacterial; Extensively Drug

2021